Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$18.84
-0.8%
$18.15
$16.36
$48.45
$1.77B0.15,132 shs2,980 shs
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
$27.53
-1.8%
$28.68
$25.68
$37.78
$1.81B0.27237,725 shs249,331 shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$4.60
$4.76
$1.07
$11.46
$442.94M0.581.22 million shs657,066 shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$19.84
+4.0%
$20.59
$12.99
$25.59
$1.76B0.41.37 million shs1.25 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
0.00%-0.77%-7.63%-3.69%-54.21%
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
0.00%+1.96%-6.99%+1.77%-14.77%
Rezolute, Inc. stock logo
RZLT
Rezolute
0.00%-1.92%+5.26%+37.72%-28.90%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
0.00%-2.75%-12.64%-1.93%+47.51%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$18.84
-0.8%
$18.15
$16.36
$48.45
$1.77B0.15,132 shs2,980 shs
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
$27.53
-1.8%
$28.68
$25.68
$37.78
$1.81B0.27237,725 shs249,331 shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$4.60
$4.76
$1.07
$11.46
$442.94M0.581.22 million shs657,066 shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$19.84
+4.0%
$20.59
$12.99
$25.59
$1.76B0.41.37 million shs1.25 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
0.00%-0.77%-7.63%-3.69%-54.21%
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
0.00%+1.96%-6.99%+1.77%-14.77%
Rezolute, Inc. stock logo
RZLT
Rezolute
0.00%-1.92%+5.26%+37.72%-28.90%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
0.00%-2.75%-12.64%-1.93%+47.51%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
3.20
Buy$46.43146.38% Upside
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
2.25
Hold$30.6711.39% Upside
Rezolute, Inc. stock logo
RZLT
Rezolute
2.50
Moderate Buy$9.38103.80% Upside
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.85
Moderate Buy$41.91111.24% Upside

Current Analyst Ratings Breakdown

Latest RZLT, SNDX, LKFT, and AAPG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
Lower Price TargetEqual Weight$30.00 ➝ $26.00
8/11/2026
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
Lower Price TargetSector Perform$28.00 ➝ $26.00
8/11/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Lower Price TargetOverweight$44.00 ➝ $40.00
8/5/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Reiterated RatingBuy
8/5/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Lower Price TargetBuy$40.00 ➝ $38.00
8/4/2026
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
DowngradeHold (C)Hold (C-)
7/30/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Reiterated RatingBuy
7/28/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
DowngradeSell (D-)Sell (E+)
7/17/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Reiterated RatingSell (D-)
7/16/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
DowngradeHoldStrong Sell
7/15/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Reiterated RatingBuy$40.00
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$82.10M21.44N/AN/A$2.04 per share9.24
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
$1.26B1.44$0.73 per share37.92$57.58 per share0.48
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$1.86 per shareN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$172.35M10.20N/AN/A$0.17 per share116.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-$177.71MN/AN/AN/AN/AN/AN/AN/AN/A
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
$363.05M-$1.41N/AN/AN/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
-$74.41M-$0.82N/AN/AN/AN/A-58.82%-54.48%9/16/2026 (Estimated)
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$285.42M-$2.51N/AN/AN/A-87.52%-372.94%-39.11%11/2/2026 (Estimated)

Latest RZLT, SNDX, LKFT, and AAPG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
-$0.9672$0.04+$1.0072$0.04$7.29 million$15.47 million
8/4/2026Q2 2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$0.4477-$0.55-$0.1023-$0.55$79.36 million$72.79 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/A
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
0.57
1.79
1.77
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
N/A
32.84
30.30
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
15.84
15.84
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
38.95
6.77
6.44
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
60093.39 millionN/AN/A
Lakefront Biotherapeutics American Depositary Shares stock logo
LKFT
Lakefront Biotherapeutics American Depositary Shares
1,31065.90 million63.98 millionOptionable
Rezolute, Inc. stock logo
RZLT
Rezolute
4096.29 million82.06 millionOptionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
11088.61 million84.36 millionOptionable

Recent News About These Companies

Syndax (SNDX) Q2 2026 Earnings Call Transcript
Q3 EPS Forecast for Syndax Pharmaceuticals Cut by Analyst
Syndax Pharmaceuticals (SNDX) Q2 2026
Syndax: Q2 Earnings Snapshot
Syndax Pharmaceuticals Q2 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascentage Pharma Group International stock logo

Ascentage Pharma Group International NASDAQ:AAPG

$18.84 -0.16 (-0.82%)
Closing price 08/14/2026 03:37 PM Eastern
Extended Trading
$18.71 -0.13 (-0.71%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Lakefront Biotherapeutics American Depositary Shares stock logo

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$27.53 -0.51 (-1.82%)
As of 08/14/2026 04:00 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Rezolute stock logo

Rezolute NASDAQ:RZLT

$4.60 0.00 (0.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$4.60 0.00 (-0.11%)
As of 08/14/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$19.84 +0.76 (+3.98%)
As of 08/14/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.